> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# SEC Charges 3 with Insider Trading at Ariad Pharma
- URL: https://www.fdaweb.com/sec-charges-3-with-insider-trading-at-ariad-pharma/
- Published: 2017-06-27T12:00:00.000Z
- Updated: 2026-09-14T22:31:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139033

The Securities and Exchange Commission has filed insider trading charges against two former employees and the spouse of a former employee of Ariad Pharmaceuticals for allegedly trading in advance of FDA decisions that impacted the sales and marketing of the company’s main cancer drug. According to the SEC’s complaint, **Harold Altvater**, whose wife was an Ariad employee, made multiple illegal trades in Ariad stock based on non-public information he obtained from her. Former Ariad executive **Maureen Curran** sold Ariad stock 12/2012 after attending meetings with the agency and learning had material nonpublic information. And former executive **Susan Dubuc** allegedly tipped off relatives before an announcement in 2013 that there would be a pause in all clinical trials for its FDA-approved drug.